ONGOING STUDIES

• IELSG4925 November 2021
  IELSG49 Phase II trial of acalabrutinib in combination with tafasitamab in patients with previously treated marginal zone lymphomas (MZL) Participants required: 24 […]
• IELSG449 December 2020
  IELSG44 FDG-PET evaluation for marginal zone lymphoma and its prognostic role: an international multicenter retrospective analysis (PIMENTO) Participants required: 350 Investigator responsible(s): […]
• IELSG47 Study4 October 2019
  MALIBU trial – Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas

LATEST NEWSLETTER

• Newsletter Number 5330 November 2021

  Click here to open pdf file

• Newsletter Number 5224 February 2020
  Click here to open pdf file

PUBLICATIONS

• MATRix–RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial1 February 2021
  Lancet Haematol 2021; 8: e110-21. Authors: Ferreri AJM, Doorduijn JK, Re A, Cabras MG, Smith J, Ilariucci F, Luppi M, Calimeri T, Cattaneo C, Khwaja J, Botto B, Cellini C, Nassi L, Linton K, McKay P, Olivieri J, Patti C, Re F, Fanni A, Singh V, Bromberg JCE, Cozens K, Gastaldi E, Bernardi M, Cascavilla N, Davies A, Fox CP, Frezzato M, Osborne W, Liberati AM, Novak U, Zambello R, Zucca E, Cwynarski K, for the International Extranodal Lymphoma Study Group (IELSG)
• Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment26 October 2020
  Haematologica. 2020 Jan 2. pii: haematol.2019.237990. doi: 10.3324/haematol.2019.237990. Epub 2020 Jan 2. Authors: Conconi A, Thieblemont C, Cascione L, Torri V, Kiesewetter B, Margiotta Casaluci G, Gaidano G, Raderer M, Cavalli F, Lopez Guillermo A, Johnson PW, Zucca E.